Christian Probst gives an overview of GSK Norway’s broad portfolio, market access hurdles, and the importance of bringing clinical trials back to Norway. Probst also touches on how the country’s impressive digital footprint can be better leveraged and GSK’s role in Norway as one of the world’s leading vaccine companies.
In the past, public-private collaborations and partnerships were seen negatively in Norway and although we are not yet at the final destination, huge progress has been made
Sissel Lønning Andresen explains how Pfizer Norway has been a pioneer of digital communication channels for years, what other Pfizer affiliates can learn from Norway in this field, and how…
Roche Diagnostics Norway’s Daniel Malarek discusses the resurgence of diagnostics in the wake of the COVID-19 pandemic, the Norwegian approval process for diagnostic tools, and the importance of stakeholder education.…
Filip Standaert outlines the significance of the Nordic cluster to J&J’s medical device operations in Europe, how the affiliate responded to the COVID-19 crisis, and the ways in which J&J…
Norway has been a global frontrunner in collecting health data and building unique registries for decades but has struggled to utilise and benefit from them. Karita Bekkemellem, CEO of the…
The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with a yawning gap still existing between vaccination rates in developed and developing economies and…
Equality has long been a deeply held ideal in Norway, where the concept of allemannsretten – the legal right to roam – permeates all aspects of society. Notably, surplus wealth…
See our Cookie Privacy Policy Here